OmicInsight
OmicInsight is a privately held biotechnology company developing the AI-powered Esper spatial omics platform, which combines proprietary Synthetic Aperture Optics with subcellular imaging to serve global biopharma companies and academic institutions in drug discovery research.
- Company typePrivate
- Founded2024
- HeadquartersSanta Clara, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What OmicInsight does
OmicInsight Corporation is a privately held biotechnology company founded in 2024 and headquartered in Santa Clara, California (incorporated in Delaware). The company develops an AI-powered spatial omics platform branded as Esper, which combines gold-standard RNA FISH chemistry with proprietary Synthetic Aperture Optics (SAO) technology to deliver high-resolution, subcellular-level molecular analysis for biopharma research. The platform's claimed performance metrics — 60x oil-immersion resolution using only a 20x air lens, 250nm subcellular resolution across tissue areas, 5x greater gene detection sensitivity than competitors, and 50x-100x higher throughput than conventional high-resolution imaging methods — underpin a positioning around cost-efficient, high-fidelity spatial biology at scale.
The company serves global biopharma companies engaged in drug discovery, mechanism-of-action studies, and PK/PD research, as well as academic research institutions reached through its North American channel partnership with Psomagen. OmicInsight's revenue streams are spatial omics analysis services and platform access/licensing on subscription/recurring terms, with quote-based enterprise pricing rather than a published rate card. Go-to-market combines direct enterprise field sales to pharmaceutical companies with channel distribution through Psomagen, co-marketing with Gradiant Bioconvergence (GBCC) in the organoid vertical, and technology showcase events. In February 2026, OmicInsight unveiled Project Cortex, a Bio-Physical AI roadmap designed to integrate AI directly into laboratory hardware for autonomous experimental control and patient-specific assay design, with an active joint research collaboration with an unnamed top-tier global pharmaceutical firm.
OmicInsight firmographics
Firmographics- Name
- OmicInsight
- Legal name
- OmicInsight Corporation
- Website
- https://omicinsight.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- OmicInsight is a privately held biotechnology company developing the AI-powered Esper spatial omics platform, which combines proprietary Synthetic Aperture Optics with subcellular imaging to serve global biopharma companies and academic institutions in drug discovery research.
- Ownership category
- akta.pro rank
OmicInsight industry classification
Industry- Product category
- Spatial Omics Analysis Platform
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Laboratory Analytical Instruments (3826), Optical Instruments & Lenses (3827)
- akta.pro primary industry
- Single-Cell & Spatial Omics Services (HLAGANAC)
- akta.pro secondary industries
- Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)
Keywords
Where OmicInsight is headquartered
LocationHeadquarters
- HQ city
- Santa Clara
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
OmicInsight business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Spatial Omics Analysis Services: High-resolution spatial omics analysis services offered to biopharma companies for drug discovery, mechanism of action studies, and PK/PD research. Services include subcellular-level multi-omics analysis at scale.
- Platform Access and Licensing: Access to the Esper Platform for high-resolution imaging and multi-omics analysis capabilities. Channel partnerships through Psomagen expanding commercial reach.
Go-to-market motion3 records
Distribution channels2 records
Marketing channels5 records
OmicInsight product offering
Product offeringCore offering
OmicInsight develops and sells the Esper Platform, an AI-powered spatial omics analysis platform that combines gold-standard RNA FISH chemistry with proprietary Synthetic Aperture Optics (SAO) technology to deliver subcellular-resolution molecular imaging, single-molecule sensitivity, and customizable AI-driven analysis pipelines for biopharma drug discovery and precision medicine. The company is developing Project Cortex, a Bio-Physical AI platform integrating artificial intelligence directly into laboratory hardware for autonomous experimental control, and offers spatial omics analysis services to pharmaceutical companies and research institutions.
Product overview
OmicInsight offers a unified platform architecture centered on the Esper Platform for spatial omics analysis. The platform integrates proprietary Synthetic Aperture Optics (SAO) technology enabling 60x oil-immersion resolution and 5x greater sensitivity than competitors. The company is developing Project Cortex, a Bio-Physical AI roadmap that extends the platform with autonomous laboratory capabilities. The product portfolio also includes associated SAO technology as the underlying optical innovation powering the platform's high-fidelity imaging capabilities.
Differentiator
Problem solved
Functional benefit
Brands
- Esper Platform: Integrated platform combining gold-standard RNA FISH chemistry with proprietary Synthetic Aperture Optics (SAO) technology for high-fidelity spatial analysis, delivering unprecedented sensitivity and resolution at reduced cost. Features include 60x oil-immersion resolution using a 20x air lens, 250nm resolution across tissue areas, and AI-driven insights for drug discovery and precision medicine.
Products and services
- Esper Platform AI-powered spatial omics platform that combines gold-standard RNA FISH chemistry with proprietary Synthetic Aperture Optics (SAO) technology to deliver unprecedented sensitivity and resolution for molecular analysis within biological tissues, enabling single-molecule detection, high-resolution imaging, and customizable analysis pipelines for drug discovery and precision medicine.
- Project Cortex (Bio-Physical AI Platform) Bio-Physical AI platform integrating artificial intelligence directly into laboratory hardware for real-time autonomous experimental control, featuring industrial-scale high-fidelity data generation, self-optimizing adaptive experimental system, closed-loop feedback adjustment of laser power, flow speed, and reagent concentration, and AI-designed patient-specific diagnostic assays for precision medicine.
- Spatial Omics Analysis Services High-resolution spatial omics analysis services offered to biopharma companies for drug discovery, mechanism of action studies, and PK/PD research, including subcellular-level multi-omics analysis at scale delivered to pharmaceutical enterprises and channel partner networks.
Quantifiable outcome
- 5x greater gene detection sensitivity than current market competitors
- +3 more outcomes
Companies that use OmicInsight
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
OmicInsight technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature7 records
OmicInsight partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered major.
- Top-tier global pharmaceutical firm (unnamed)majorJoint research collaboration on Project Cortex Bio-Physical AI platform. The unnamed pharmaceutical firm is engaged in joint research to develop and validate the autonomous laboratory technology for drug discovery applications.
- Psomagen, Inc.majorMarketing agreement where Psomagen offers OmicInsight's high-resolution imaging and multi-omics analysis capabilities as part of Psomagen's spatial transcriptomics service portfolio. Psomagen, headquartered in Rockville, MD, is a premier North American provider of transcriptomic and genomic services with over 20 years of experience serving top-tier academic and pharmaceutical institutions. Acts as channel partner introducing OmicInsight's specialized services to their extensive client network including world-class research institutions and leading global pharmaceutical companies.
- Gradiant Bioconvergence (GBCC)majorStrategic co-marketing agreement to jointly advance research at the interface of spatial biology and organoid science. Partnership combines OmicInsight's high-sensitivity spatial transcriptomics platform with GBCC's next-generation organoid models to enable unprecedented clarity and accessibility for researchers. Anticipated platform to reshape drug discovery, precision medicine, and regenerative medicine. GBCC headquartered in Seoul, South Korea is an organoid-based platform company integrating PDO banking system with AI and genomics analytics.
Scale indicators7 records
Recent moves6 records
Expansion highlights8 records
OmicInsight competitors and assessment
Company assessmentBroad incumbents
- Bio-Techne: Bio-Techne's RNAscope ISH technology is a long-established gold-standard spatial RNA platform serving pharma and academic customers, overlapping with OmicInsight's claims of gold-standard RNA FISH chemistry integration within Esper.
Direct peers
- Resolve Biosciences: Resolve Biosciences offers Molecular Cartography spatial transcriptomics with subcellular resolution, targeting biopharma discovery and translational researchers with similar use cases to OmicInsight's Esper platform.
- 10x Genomics: 10x Genomics is the dominant spatial transcriptomics and single-cell omics platform company (Xenium, Visium HD, Chromium). It directly competes with OmicInsight's Esper platform for biopharma and academic research budgets targeting subcellular-resolution spatial omics.
- Standard BioTools: Standard BioTools (formerly Fluidigm) provides Hyperion imaging mass cytometry for spatial proteomics. It serves the same biopharma biomarker discovery use cases with comparable per-tissue-area high-multiplex workflows.
- Vizgen: Vizgen commercializes MERFISH-based spatial transcriptomics instruments for subcellular gene expression profiling. Vizgen competes directly with OmicInsight's Esper platform on subcellular-resolution spatial RNA analysis for pharma and academic researchers.
- Akoya Biosciences: Akoya's PhenoCycler (CODEX) and OPAL multiplexed immunofluorescence platforms compete in the high-plex spatial proteomics and tissue imaging markets that OmicInsight targets with its Esper platform for biopharma biomarker discovery.
- Bruker Spatial Biology (formerly NanoString): Bruker acquired NanoString's spatial biology business including CosMx SMI and GeoMx digital spatial profiling. CosMx is the closest head-to-head competitor to Esper in high-plex single-cell spatial RNA analysis for biopharma translational research.
Others
- Leica Microsystems: Leica (Danaher) is a major microscopy and sample-prep instrument supplier feeding into spatial omics workflows. It is a complementary/adjacent provider of high-resolution optical instruments relevant to OmicInsight's SAO optics roadmap rather than a direct spatial omics competitor.
- Abcam (Danaher): Abcam supplies antibody reagents widely used in spatial proteomics and immunohistochemistry workflows. As a complementary reagent/antibody provider, it enables OmicInsight's protein-RNA co-detection use cases without directly competing.
- Carl Zeiss Microscopy: ZEISS is a leading microscopy and optics manufacturer whose high-resolution objectives and imaging platforms underpin much of the spatial biology ecosystem. It is an adjacent optical-instrumentation vendor relevant to the SAO optics build-out.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
OmicInsight social profiles
Digital presenceOmicInsight financial estimates
Financial estimateRevenue estimate
Valuation estimate
OmicInsight leadership team
Management profileNumber of profiles
Profiles3 records
OmicInsight funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OmicInsight M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OmicInsight
What does OmicInsight do?
OmicInsight develops and sells the Esper Platform, an AI-powered spatial omics analysis platform that combines gold-standard RNA FISH chemistry with proprietary Synthetic Aperture Optics (SAO) technology to deliver subcellular-resolution molecular imaging, single-molecule sensitivity, and customizable AI-driven analysis pipelines for biopharma drug discovery and precision medicine. The company is developing Project Cortex, a Bio-Physical AI platform integrating artificial intelligence directly into laboratory hardware for autonomous experimental control, and offers spatial omics analysis services to pharmaceutical companies and research institutions.
Is OmicInsight a public or private company?
OmicInsight is a private company. It is classified as venture growth investor backed and is currently operating.
When was OmicInsight founded?
OmicInsight was founded in 2024. It employs 1 to 10 people.
Where is OmicInsight based?
OmicInsight is headquartered in Santa Clara, United States, in the North America region.
How does OmicInsight make money?
Two revenue lines are on record. Spatial Omics Analysis Services are the primary driver. The others are platform Access and Licensing.
Who are OmicInsight's main competitors?
Bio-Techne is listed as a broad incumbent. Direct peers are Resolve Biosciences, 10x Genomics, Standard BioTools, Vizgen, Akoya Biosciences and Bruker Spatial Biology (formerly NanoString). Others are Leica Microsystems, Abcam (Danaher) and Carl Zeiss Microscopy.
Does OmicInsight have an API?
No public API is recorded for OmicInsight.
What industry is OmicInsight in?
OmicInsight's product category is Spatial Omics Analysis Platform. Its primary akta.pro industry code is HLAGANAC, Single-Cell & Spatial Omics Services, with a secondary code of HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling). Its NAICS code is 334516 and its SIC code is 3826.